Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”

Privo is excited to share the recent Forbes article titled, “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems” written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform.    Click the below to access the fill Forbes article.

Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems (forbes.com)

Link to Nature Communications publication on the PRV Platform is also provided below.

A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer | Nature Communications

Media Contact: communicationteam@privotechnologies.com 

September 8, 2022

Share this post

Author

Related Posts

14Nov

Privo Technologies earns first ever runner-up placement at the Salisbury Award competition in Bethesda, Maryland.

The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at... read more

12Aug

Privo Technologies, Inc. Receives 3rd U.S. FDA Orphan Drug Designation

Peabody, MA  – Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug... read more

01Aug

Privo receives a $220,000 Award from the National Institute of Dental and Craniofacial Research (NIDCR)

Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

01Apr

National Cancer Institute awards

Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more

07Dec

Privo Technologies, Inc. To Attend Bio Partnering at JPM January 10 to January 14, 2022

Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

20Aug

Privo Technologies, Inc. Awarded $3M NIDCR NIH Commercialization Readiness Pilot Grant

Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy... read more

02Dec

Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

25Feb

Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors

Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced... read more

19Aug

Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more

04Feb

Privo Technologies, Inc. To Present at the 24th Annual BIO CEO & Investor Conference

Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

Contact Us
close slider

Contact Us